Go to content

Publications

467 publications

Enter search criteria
Fill in keyword(s) to narrow your search.
Period
You can select a specific type of a publication you are looking for, such as press releases or speeches
Sort by:

  1. Package advice on zanubrutinib (Brukinsa®) for the treatment of Waldenström macroglobulinaemia (WM)

    The National Health Care Institute advises the Minister to include zanubrutinib (Brukinsa®) in the basic health insurance package ...

    Report | 27-04-2022

  2. GVS advice on dabigatran etexilate (Pradaxa®) capsules extension further conditions

    The National Health Care Institute advises the Minister to amend List 2 of the GVS to extend the reimbursement of dabigatran ...

    Report | 25-04-2022

  3. International strategic agenda 2022-2023 National Health Care Institute

    The international strategic agenda 2022-2023 describes the international activities of the National Health Care Institute ...

    Publication | 21-04-2022

  4. GVS advice ivermectin (Stromectol®)

    The National Health Care Institute advises the Minister to include ivermectin (Stromectol®) in List 1B and List 2 of the GVS. ...

    Report | 20-04-2022

  5. GVS advice avacopan (Tavneos®)

    The National Health Care Institute advises the Minister not to include avacopan (Tavneos®) in the GVS. Avacopan is indicated for ...

    Report | 20-04-2022

  6. GVS advice on finerenon (Kerendia®)

    The National Health Care Institute advises the Minister to include finerenon (Kerendia®) in List 1B of the GVS. Finerenon is ...

    Report | 04-04-2022

  7. GVS advice extension further conditions for dapagliflozin (Forxiga®)

    The National Health Care Institute has completed its assessment whether the further conditions for dapagliflozin (Forxiga®) could ...

    Report | 28-03-2022

  8. GVS advice extension further conditions for elexacaftor/tezacaftor/ivacaftor (Kaftrio®) in combination with ivacaftor (Kalydeco®)

    The National Health Care Institute has completed its assessment whether the further conditions of ...

    Report | 22-03-2022

  9. Package advice cabozantinib in combination with nivolumab (Cabometyx-Opdivo®)

    The National Health Care Institute advises the Minister to include cabozantinib in combination with nivolumab (Cabometyx® in ...

    Report | 14-03-2022

  10. GVS advice liraglutide (Saxenda®), extension of further conditions for certain people with an extremely increased weight-related health risk

    The National Health Care Institute advises the Minister to extend the List 2 conditions for liraglutide (Saxenda®). The ...

    Report | 24-02-2022

Go to